* 10X Genomics Inc reported a quarterly adjusted loss of 50 cents per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -44 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -65 cents to -30 cents per share.
* Revenue rose 5% to $141.01 million from a year ago; analysts expected $142.25 million.
* 10X Genomics Inc's reported EPS for the quarter was a loss of 50 cents.
* The company reported a quarterly loss of $59.95 million.
* 10X Genomics Inc shares had fallen by 24.3% this quarter and lost 49.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 11.7% in the last three months.
* In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for 10X Genomics Inc is $53.50 This summary was machine generated from LSEG data April 30 at 09:51 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.50 -0.50 Met
Dec. 31 2023 -0.36 -0.41 Missed
Sep. 30 2023 -0.46 -0.79 Missed
Jun. 30 2023 -0.40 -0.53 Missed
Comments